An approximately $64-M DNA delivery deal with Inovio adds to its $212-agreement with Ablynx.
Inovio Biomedical granted Wyeth Pharmaceuticals a worldwide nonexclusive license to its DNA delivery technology for intramuscular applications of certain therapeutic DNA vaccines. Inovio will exclusively supply Wyeth with electroporation devices for the vaccines included in the license agreement.
Under the terms of the agreement, Inovio will receive a $4.5-million upfront license fee, annual license maintenance fees, research support, up to $60 million in payments based on successful completion of clinical and regulatory milestones, and royalties on the sale of products covered by the license.
This comes after Wyeth Pharmaceuticals signed a $212.5-M exclusive research collaboration and license agreement with Ablynx regarding Nanobodies® directed at the tumor necrosis factor alpha protein and its receptors that target diseases in multiple therapeutic areas.
